Appendix 5. Therapeutic benefit rating methods

Steps	Organizations	Major	Moderate	Little to no
Main analysis				
Step 1: the highest rating of the three organizations	PMPRB https://www.canada.ca/en/patented-medicine-prices-review/services/annual-reports.html	Breakthrough, substantial improvement	Moderate improvement – primary, moderate improvement –secondary	Slight or no improvement
	IQWiG https://www.iqwig.de/en/presse/media-centre/annual-reports/	Major added benefit	Considerable added benefit	Minor added benefit, non-quantifiable added benefit, no added benefit, less benefit
	Prescrire International https://english.prescrire.org/en/81/168/46800/0/NewsDetails.aspx https://english.prescrire.org/en/81/168/64261/0/NewsDetails.aspx	Bravo, a real advance	Offers an advantage	Possibly helpful, nothing new, not acceptable
Step 2: molecules with missing ratings after Step 1 were rated as major benefit based on US FDA designation of breakthrough therapy	FDA CDER https://www.fda.gov/drugs/nda-and-bla-approvals/breakthrough-therapy-approvals	Breakthrough therapy approvals		
Sensitivity analysis				
Step 3: molecules with missing ratings after Step 2 were rated based on US FDA designation of first-in-class and priority review	FDA CDER https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/new-drug-therapy-approvals-2022	first-in-class and priority review approvals	first-in-class or priority review approvals but not both	Neither first-in-class nor priority review approvals

PMPRB: the Patented Medicine Prices Review Board; IQWiG: the Institute for Quality and Efficiency in Health Care; US: the United States; FDA: Food and Drug Administration; CDER: Center for Drug Evaluation and Research